To analyze the clinical effect of Shenqi Fuzheng Kang’ai Decoction（参芪扶正抗癌汤）combined with bevacizumab in the treatment of advanced colorectal cancer with Qiand blood deficiency syndrome.

The clinical data of 98 patients with advanced colorectal cancer who were admitted to the Affiliated Hospital of Nantong University from January 2022 to January 2024 was retrospectively analyzed.According to the treatment methods，they were divided into the conventional group（48 cases）and the combined group（50 cases）.Both groups were treated with XELOX chemotherapy.The conventional group was treated with bevacizumab，and the combined group was treated with Shenqi Fuzheng Kang’ai Decoction on this basis.The TCM syndrome score，tumor markers，T lymphocyte subsets，chemotherapy tolerance and quality of life score，clinical efficacy，adverse reactions and survival analysis of the two groups were observed.

After treatment，the TCM syndrome score and the levels of carcinoembryonic antigen（CEA），carbohydrate antigen 125（CA125），alpha-fetoprotein（AFP）and cytokeratin 19 fragment antigen 21-1（CYFRA21-1）in the combined group were lower than those in the conventional group（P<0.05）.The levels of CD3⁺and CD4⁺，the ratio of CD4⁺/CD8⁺，the scores of Karnofsky performance scale（KPS）and World Health Organization Quality of Life-BREF（WHOQOL-BREF）and the total effective rate in the combined group were higher than those in the conventional group（P<0.05）.There was no significant difference in the total incidence of adverse reactions between the two groups（P>0.05）.The progression-free survival（PFS）of the combined group was longer than that of the conventional group（P<0.05）.

Shenqi Fuzheng Kang’ai Decoction combined with bevacizumab in the treatment of advanced colorectal cancer with Qi and blood deficiency syndrome can effectively relieve the clinical symptoms of patients，improve the immunity，reduce the levels of tumormarkers，improve the clinical efficacy and quality of life，prolong the survival of patients，and has high safety.